BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 21856592)

  • 1. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies.
    Bays HE
    Endocr Pract; 2011; 17(6):933-8. PubMed ID: 21856592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.
    Rosenstock J; Fonseca VA; Garvey WT; Goldberg RB; Handelsman Y; Abby SL; Lai YL; Jin X; Misir S; Nagendran S; Jones MR
    Endocr Pract; 2010; 16(4):629-40. PubMed ID: 20634175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis.
    Jialal I; Abby SL; Misir S; Nagendran S
    Metab Syndr Relat Disord; 2009 Jun; 7(3):255-8. PubMed ID: 19344229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus.
    Goldberg RB; Rosenson RS; Hernandez-Triana E; Misir S; Jones MR
    J Clin Lipidol; 2012; 6(4):318-24. PubMed ID: 22836068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
    Bays HE; Goldberg RB; Truitt KE; Jones MR
    Arch Intern Med; 2008 Oct; 168(18):1975-83. PubMed ID: 18852398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
    Fonseca VA; Rosenstock J; Wang AC; Truitt KE; Jones MR
    Diabetes Care; 2008 Aug; 31(8):1479-84. PubMed ID: 18458145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of colesevelam HCl in the treatment of elderly patients.
    Gavin JR; Jones MR; Ford DM; Truitt KE
    Drugs Aging; 2014 Jun; 31(6):461-70. PubMed ID: 24777691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
    Simons WR; Hagan MA
    Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes.
    Rosenstock J; Hernandez-Triana E; Handelsman Y; Misir S; Jones MR; Nagendran S
    Postgrad Med; 2012 Jul; 124(4):7-13. PubMed ID: 22913889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study.
    Handelsman Y; Goldberg RB; Garvey WT; Fonseca VA; Rosenstock J; Jones MR; Lai YL; Jin X; Misir S; Nagendran S; Abby SL
    Endocr Pract; 2010; 16(4):617-28. PubMed ID: 20634176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
    Zieve FJ; Kalin MF; Schwartz SL; Jones MR; Bailey WL
    Clin Ther; 2007 Jan; 29(1):74-83. PubMed ID: 17379048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes.
    Rosenson RS; Abby SL; Jones MR
    Atherosclerosis; 2009 Jun; 204(2):342-4. PubMed ID: 18996525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol).
    Mazze RS; Strock ES; Monk AM; Murphy MM; Xi M; Bergenstal RM
    Endocr Pract; 2013; 19(2):275-83. PubMed ID: 23598534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
    Bays H; Rhyne J; Abby S; Lai YL; Jones M
    Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
    Goldberg RB; Fonseca VA; Truitt KE; Jones MR
    Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of colesevelam HCl in type 2 diabetes mellitus therapy.
    Handelsman Y
    Postgrad Med; 2009 May; 121(3 Suppl 1):19-24. PubMed ID: 19494474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.
    Rosenstock J; Hernandez-Triana E; Handelsman Y; Misir S; Jones MR
    Postgrad Med; 2012 Jul; 124(4):14-20. PubMed ID: 22913890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucose and lipid effects of colesevelam as monotherapy in drug-naïve type 2 diabetes.
    Rosenstock J; Rigby SP; Ford DM; Tao B; Chou HS
    Horm Metab Res; 2014 May; 46(5):348-53. PubMed ID: 24356792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
    Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AF; Imholz BP; Durrington PN; Trip MD; Eriksson M; Visseren FL; Schaefer JR; Kastelein JJ;
    Clin Ther; 2010 Apr; 32(4):615-25. PubMed ID: 20435231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.